GH Research (NASDAQ:GHRS) Receives “Buy” Rating from HC Wainwright

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $40.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 385.44% from the stock’s current price.

Separately, JMP Securities reissued a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday.

GH Research Price Performance

GHRS stock traded down $0.23 during mid-day trading on Thursday, reaching $8.24. 13,777 shares of the company traded hands, compared to its average volume of 85,569. GH Research has a 52-week low of $5.05 and a 52-week high of $14.99. The company has a market capitalization of $428.71 million, a P/E ratio of -13.29 and a beta of 0.86. The company has a fifty day moving average price of $11.25 and a 200-day moving average price of $11.19.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. As a group, analysts forecast that GH Research will post -0.84 EPS for the current year.

Institutional Investors Weigh In On GH Research

Large investors have recently added to or reduced their stakes in the company. AdvisorShares Investments LLC grew its holdings in shares of GH Research by 4.3% during the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock valued at $280,000 after purchasing an additional 1,977 shares during the last quarter. Lynx1 Capital Management LP lifted its stake in GH Research by 80.1% in the first quarter. Lynx1 Capital Management LP now owns 3,310,563 shares of the company’s stock worth $35,291,000 after purchasing an additional 1,471,946 shares during the last quarter. BVF Inc. IL boosted its position in GH Research by 12.1% during the fourth quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after buying an additional 1,125,000 shares during the period. Finally, RA Capital Management L.P. grew its stake in shares of GH Research by 11.9% during the first quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock valued at $66,643,000 after buying an additional 664,381 shares during the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).